Neurogene Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 16.92 million compared to USD 12.26 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 28.28 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
37.87 USD | +0.37% | +13.59% | +95.41% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.41% | 490M | |
+55.64% | 55.7B | |
+41.08% | 39.91B | |
-5.59% | 39.57B | |
-5.56% | 28.16B | |
+16.14% | 26.3B | |
-20.60% | 18.94B | |
+32.91% | 12.17B | |
+25.90% | 12.12B | |
+2.60% | 12.12B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024